Atezolizumab

3 articles published between March 25, 2026 and September 25, 2026.

WHAT THE STUDY ACTUALLY SAYS

Adding immunotherapy to radiation did not help early-stage lung cancer survival

In the phase 3 SWOG/NRG S1914 trial, adding atezolizumab to stereotactic radiotherapy for high-risk, inoperable early lung cancer left 2-year survival at 82% in both groups and caused more serious side effects.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Adding atezolizumab to chemo did not clearly help early triple-negative breast cancer

In the NSABP B-59 trial, adding the immunotherapy to neoadjuvant chemotherapy did not significantly improve event-free survival, while immune-related side effects more than doubled.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Adding immunotherapy to chemo cuts relapse in mismatch-repair-deficient colon cancer

In the phase 3 ATOMIC trial, atezolizumab on top of standard FOLFOX chemotherapy raised three-year disease-free survival to 86.3% from 76.2% after surgery for stage III dMMR colon cancer.

4 min read

This page indexes this newspaper’s reporting on Atezolizumab. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.